Total Payments
$2,481
2024 Payments
$607.05
Companies
30
Transactions
109
Medicare Patients
1,517
Medicare Billing
$341,705
Payment Breakdown by Category
Food & Beverage$2,481 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,481 | 109 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $702.84 | 40 | $0 (2024) |
| SK Life Science, Inc. | $225.33 | 9 | $0 (2024) |
| Biogen, Inc. | $153.30 | 8 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $149.84 | 4 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $146.22 | 6 | $0 (2024) |
| LivaNova USA, Inc. | $145.49 | 5 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $116.74 | 2 | $0 (2022) |
| Neuronetics, Inc. | $113.47 | 1 | $0 (2020) |
| Eisai Inc. | $85.93 | 4 | $0 (2023) |
| ACADIA Pharmaceuticals Inc | $62.82 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $607.05 | 23 | ABBVIE INC. ($180.75) |
| 2023 | $343.35 | 16 | ABBVIE INC. ($90.91) |
| 2022 | $746.33 | 35 | ABBVIE INC. ($271.38) |
| 2021 | $516.62 | 25 | AbbVie Inc. ($159.80) |
| 2020 | $217.44 | 7 | Neuronetics, Inc. ($113.47) |
| 2019 | $19.23 | 1 | Biogen, Inc. ($19.23) |
| 2018 | $30.93 | 2 | Otsuka America Pharmaceutical, Inc. ($19.67) |
All Payment Transactions
109 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Amneal Pharmaceuticals LLC | RYTARY (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: NEUROLOGY | ||||||
| 12/10/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Food and Beverage | In-kind items and services | $36.53 | General |
| Category: Neurology | ||||||
| 12/09/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $95.85 | General |
| Category: Neuroscience | ||||||
| 09/24/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: Neurology | ||||||
| 09/19/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $8.98 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: Neuropsychiatry | ||||||
| 09/03/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: Neurology | ||||||
| 08/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.22 | General |
| Category: NEUROSCIENCE | ||||||
| 06/14/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $24.16 | General |
| 06/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: NEUROSCIENCE | ||||||
| 05/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: NEUROSCIENCE | ||||||
| 05/06/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Food and Beverage | In-kind items and services | $32.33 | General |
| Category: Neurology | ||||||
| 04/18/2024 | ACADIA Pharmaceuticals Inc | DAYBUE (Drug) | Food and Beverage | In-kind items and services | $30.56 | General |
| Category: RETT SYNDROME | ||||||
| 04/10/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $27.39 | General |
| Category: PSYCHIATRY | ||||||
| 04/04/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $11.37 | General |
| Category: NEUROSCIENCE | ||||||
| 03/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.13 | General |
| Category: NEUROSCIENCE | ||||||
| 03/12/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: CNS | ||||||
| 02/29/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: Neurology | ||||||
| 02/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: NEUROSCIENCE | ||||||
| 02/06/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: PAIN MANAGEMENT | ||||||
| 02/01/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $21.71 | General |
| Category: PSYCHIATRY | ||||||
| 01/10/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: NEUROSCIENCE | ||||||
| 10/26/2023 | Lilly USA, LLC | AMYVID (Drug) | Food and Beverage | In-kind items and services | $29.26 | General |
| Category: Neuroscience | ||||||
| 09/26/2023 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 368 | 1,189 | $251,501 | $95,492 |
| 2022 | 10 | 413 | 1,195 | $227,709 | $88,157 |
| 2021 | 7 | 401 | 1,181 | $228,849 | $88,068 |
| 2020 | 8 | 335 | 843 | $217,178 | $69,988 |
Total Patients
1,517
Total Services
4,408
Medicare Billing
$341,705
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 97 | 477 | $66,780 | $47,197 | 70.7% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 109 | 531 | $63,720 | $28,378 | 44.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 61 | 61 | $69,475 | $8,585 | 12.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 45 | $26,400 | $4,355 | 16.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $7,750 | $4,145 | 53.5% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 17 | 18 | $14,256 | $1,737 | 12.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 26 | $3,120 | $1,095 | 35.1% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 110 | 530 | $63,040 | $28,980 | 46.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 77 | 230 | $32,020 | $23,576 | 73.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 91 | 284 | $34,080 | $18,409 | 54.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 45 | 45 | $49,285 | $7,242 | 14.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 34 | $19,056 | $2,833 | 14.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $5,000 | $2,477 | 49.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 13 | 13 | $3,250 | $1,580 | 48.6% |
| 99284 | Emergency department visit for problem of high severity | Facility | 2022 | 12 | 12 | $9,276 | $1,175 | 12.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 14 | 14 | $7,612 | $1,130 | 14.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 13 | $5,090 | $754.96 | 14.8% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 100 | 507 | $60,800 | $28,009 | 46.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 92 | 372 | $44,650 | $25,128 | 56.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 54 | 141 | $19,700 | $12,520 | 63.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 66 | 70 | $72,638 | $11,514 | 15.9% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 51 | 51 | $12,750 | $6,918 | 54.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 27 | 29 | $15,561 | $2,461 | 15.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $2,750 | $1,517 | 55.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 58 | 284 | $36,500 | $23,404 | 64.1% |
About Dr. Anthony Kelada, M.D
Dr. Anthony Kelada, M.D is a Psychiatry healthcare provider based in Roseville, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/07/2014. The National Provider Identifier (NPI) number assigned to this provider is 1659790624.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Kelada, M.D has received a total of $2,481 in payments from pharmaceutical and medical device companies, with $607.05 received in 2024. These payments were reported across 109 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($2,481).
As a Medicare-enrolled provider, Kelada has provided services to 1,517 Medicare beneficiaries, totaling 4,408 services with total Medicare billing of $341,705. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Roseville, CA
- Active Since 04/07/2014
- Last Updated 08/26/2019
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659790624
Products in Payments
- VRAYLAR (Drug) $360.79
- UBRELVY (Drug) $208.21
- REXULTI (Drug) $165.84
- SPRAVATO (Drug) $137.29
- QULIPTA (Drug) $133.84
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) $114.70
- NEUROSTAR TMS THERAPY (Device) $113.47
- INGREZZA (Drug) $112.18
- Fintepla (Drug) $85.03
- DAYBUE (Drug) $62.82
- Proclaim IPG (Device) $60.39
- Fycompa (Drug) $60.07
- Mavenclad (Drug) $35.17
- Ongentys (Drug) $34.04
- VNS Therapy SenTiva Model 1000 Generator (Device) $30.79
- TYSABRI (Biological) $30.52
- AMYVID (Drug) $29.26
- ADUHELM (Biological) $25.87
- Aduhelm (Drug) $25.86
- ULTOMIRIS (Biological) $25.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Roseville
James Adamo, M.d, M.D
Psychiatry — Payments: $25,855
Psychiatry $25,855
Jonathon Porter, D.o, D.O
Psychiatry — Payments: $4,935
Psychiatry $4,935
Dr. Prudencio Samson, Md, MD
Psychiatry — Payments: $4,745
Psychiatry $4,745
Lorerky Ramirez-Moya, Md, MD
Psychiatry — Payments: $3,832
Psychiatry $3,832
Dr. Karla De Beck, M.d, M.D
Psychiatry — Payments: $2,982
Psychiatry $2,982
Chunlin Yang, M.d, M.D
Psychiatry — Payments: $2,557
Psychiatry $2,557